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Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells
leading to intracellular drug release. Typically, only a subset of patients with solid tumours
has sufﬁcient expression of such a receptor, while there are suitable non-internalising
receptors and stroma targets. Here, we demonstrate potent therapy in murine tumour
models using a non-internalising ADC that releases its drugs upon a click reaction with a
chemical activator, which is administered in a second step. This was enabled by the
development of a diabody-based ADC with a high tumour uptake and very low retention in
healthy tissues, allowing systemic administration of the activator 2 days later, leading to
efﬁcient and selective activation throughout the tumour. In contrast, the analogous ADC
comprising the protease-cleavable linker used in the FDA approved ADC Adcetris is not
effective in these tumour models. This ﬁrst-in-class ADC holds promise for a broader
applicability of ADCs across patient populations.
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Antibody-drug conjugates (ADCs) are a promising class ofbiopharmaceuticals that combine the target-speciﬁcity ofmonoclonal antibodies (mAbs) or mAb fragments with
the potency of small molecule toxins1,2. They are designed to bind
to an internalising cancer cell receptor leading to uptake of the
ADC and subsequent intracellular release of the drug by enzymes,
thiols or lysosomal pH. Routing the toxin to the tumour, while
minimising the peripheral damage to healthy
tissue, allows the use of highly potent drugs resulting in improved
therapeutic outcomes. Presently, four ADCs are approved by the
American Food and Drug Administration (FDA): brentuximab
vedotin (Adcetris) for Hodgkin and anaplastic large cell
lymphoma, ado-trastuzumab emtansine (Kadcyla) for HER2-
positive metastatic breast cancer, gemtuzumab ozogamicin
(Mylotarg) for acute myeloid leukaemia and inotuzumab
ozogamicin (Besponsa) for the treatment of acute lymphoblastic
leukaemia. For example, Adcetris afforded a 75% overall
response rate in patients with relapsed or refractory Hodgkin
lymphoma and a median duration of response of 21 months3.
Encouraged by these ﬁrst successes, over 60 ADCs are now in
clinical trials for a variety of haematologic and solid tumour
malignancies1–3.
Nevertheless, the current strategies do have some limitations,
especially with respect to solid tumours. Haematologic tumours
typically exhibit speciﬁc and homogenous expression of the target
antigen and are well perfused and, therefore, accessible to the
ADC3,4. On the other hand, therapy of solid tumours is hampered
by the relatively limited number of suitable cancer-speciﬁc targets
and the poor intratumoral distribution of ADCs2,4. The elevated
interstitial pressure in solid tumours impedes penetration by large
constructs such as ADCs5. This penetration can also be affected
by the binding to cancer cells in the perivascular space and to
antigens in the interstitial space, shed from dying cells5–7. The
heterogeneous receptor expression observed in solid tumours
further confounds homogeneous drug delivery1,5. Importantly,
the number of solid tumour-speciﬁc receptors that ensure efﬁ-
cient internalisation and drug release is relatively limited. Low
receptor copy numbers, slow internalisation kinetics, inefﬁcient
subcellular trafﬁcking and receptor expression levels in normal
tissues all complicate the selection of solid tumour targets for the
current ADC approaches4,8,9. Furthermore, contrary to
haematologic targets, solid tumour targets are typically only
overexpressed in a subset of patient populations3,8. For example,
only 20% of breast cancer patients have sufﬁcient HER2
expression to be eligible for treatment with Kadcyla.
An approach that functions by means of extracellular drug
release would expand the number of potential ADC targets as
there are sufﬁcient non-internalising receptors and extracellular
matrix targets that are selectively present in solid tumours10–15.
Such targets may become amendable to ADC therapy by using a
bioorthogonal chemical reaction for selective antibody-drug
cleavage in vivo instead of relying on intracellular biological
activation mechanisms. In this two-step approach, tumour
binding of the ADC and blood clearance of the unbound fraction
would be followed by systemic administration of an activator that
reacts with the ADC linker, leading to drug release and sub-
sequent uptake into surrounding cancer cells as well as tumour-
supporting stromal cells (Fig. 1). Indeed, extracellular cleavage of
disulphide- and peptide-linked ADCs by endogenous mechan-
isms has recently been shown to afford therapeutic efﬁcacy in
several mouse models, while it is generally accepted that such
linkers need to be internalised to achieve sufﬁcient cleavage16,17.
Likewise, a chemically cleavable ADC system would expand the
target scope and, in contrast to the inherent variability that can
hamper endogenous mechanisms, would enable universal and
direct temporal control over drug release. Furthermore, extra-
cellular release could possibly allow more drug to diffuse into the
tumour, aiding homogenous drug delivery and the bystander
effect, thus potentially improving therapeutic efﬁcacy in hetero-
geneous or poorly penetrated tumours1,2. The fastest bioortho-
gonal (click) reaction, the inverse-electron-demand Diels−Alder
(IEDDA) conjugation between trans-cyclooctene (TCO) and
tetrazine derivatives, is now an established method for bio-
conjugations in mice18. We showed that this IEDDA conjugation
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Fig. 1 Triggered drug release using “click-to-release” chemistry in vivo: on-tumour liberation of a cell permeable drug (monomethyl auristatin E, MMAE)
from a trans-cyclooctene-linked ADC following systemic administration of a tetrazine activator
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could be transformed into an IEDDA pyridazine elimination
reaction leading to the cleavage of allylic carbamates from TCO
upon reaction with tetrazine19, opening up bioorthogonal “click-
to-release” applications in vitro and in vivo18,20–24. This reaction
seemed well suited for the envisioned chemically triggered ADC
therapy, which may address the relatively limited number of
clinically validated solid tumour targets for the current systems.
Herein, we report the ﬁrst example of such click-to-release
ADC therapy in tumour-bearing mice, enabled by the develop-
ment of a diabody conjugate with a high tumour uptake com-
bined with a fast blood clearance, and a new tetrazine activator
that gives near-quantitative drug release (Fig. 1). Biodistribution
and imaging experiments show that the ADC, comprising the
TCO-linked drug monomethyl auristatin E (MMAE) and
polyethylene glycol (PEG), matches the high tumour uptake of
the parent mAb combined with very low levels in non-target
tissues, and that the tetrazine activator can effectively reach
this conjugate throughout the tumour. Efﬁcacy studies in
two mouse xenograft models demonstrate a potent therapeutic
effect, whereas an analogous ADC containing the protease
sensitive valine-citrulline linker, used in the marketed ADC
Adcetris and designed for intracellular release, fails to control
tumour growth in both models. These ﬁndings indicate that the
click-to-release concept allows to expand the scope of ADC
therapy to non-internalising receptors and stroma targets,
forming the basis for a broader applicability across patient
populations, thus potentially lowering the hurdle for success
against solid tumours.
Results
Development of the anti-TAG72 ADC. We chose to use the
tubulin-binding antimitotic MMAE as the toxin as it is widely
used in ADCs and, essential for our approach, is cell permeable1.
Tumour-associated glycoprotein-72 (TAG72) was selected as the
cancer target, as it does not internalise, has slow shedding, and is
widely expressed in a range of epithelial-derived human adeno-
carcinomas such as breast, colorectal, stomach, lung, pancreatic,
prostate and ovarian cancer, while TAG72 expression in normal
adult tissues is very low15. The TAG72 targeting mAb CC49 has
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Fig. 2 Compounds used in this study: diabody-based ADCs tc-ADC (anti-TAG72, containing the chemically cleavable TCO linker), vc-ADC (anti-TAG72,
containing the enzymatically cleavable valine-citrulline linker), and nb-ADC (non-binding, anti-PSMA, containing the TCO linker), linker-drug building
blocks (1 and 2), and tetrazine-containing activator (3) and probe (4)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03880-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1484 | DOI: 10.1038/s41467-018-03880-y | www.nature.com/naturecommunications 3
been used in the clinic for (pretargeted) radioimmunotherapy of
ovarian, colorectal, lung, prostate and breast cancer25,26 and for
preclinical on-tumour IEDDA conjugation and elimination
reactions23,27,28. Due to the slow clearance of mAbs from blood, a
mAb-based ADC would require a very long interval between
ADC and activator administration in order to prevent undesired
drug release in circulation and well perfused tissues. To minimise
this interval, we decided to develop a faster clearing PEGylated
CC49 diabody conjugate instead. Conjugation of PEG24 residues
to a CC49 diabody had previously been shown to afford superior
imaging properties compared to both the native diabody and the
parent mAb, owing to a high tumour uptake combined with a
complete blood clearance within 2–3 days29. In addition to the
likelihood of very low off-target activation levels, a smaller ADC
lacking an Fc region could also improve tumour penetration and
preclude the toxicities from Fc cross reaction with normal tissues
as seen for current ADCs2,30. In the context of pretargeted
radioimmunoimaging it had been demonstrated that mAb-
conjugated TCO can be isomerised to the unreactive cis-isomer
through contact with copper-binding sites in the serum proteins
albumin and ceruloplasmin and that this deactivation can be
slowed down to half-lives of 5 days or more in mice by reducing
the mAb-TCO spacer length, thereby shielding the TCO31. To
achieve the same in the ADC, we prepared a drug linker com-
prising a lysine-branched spacer designed to have the TCO-
MMAE shielded by the vicinity of the diabody as well as the
PEG24 moiety (1, Fig. 2). This maleimide-functionalized TCO-
MMAE linker 1 was site-speciﬁcally conjugated to four engi-
neered cysteine residues in the CC49 diabody providing tc-ADC
(61 kDa, Fig. 2) with a drug-to-antibody ratio (DAR) of 4 and
with complete retention of immunoreactivity towards its target
TAG72 (Supplementary Fig. 9). The conjugate showed excellent
stock stability (phosphate-buffered saline (PBS), 4 °C) as no TCO
isomerisation or spontaneous drug liberation was observed in
6 months (Supplementary Figs. 2a, 2b and 4). In addition, no
drug release was observed upon incubation of the ADC in serum
at 37 °C for 24 h (Supplementary Fig. 6).
Next, we examined the pharmacokinetics of intravenous (i.v.)
administered 125I-labelled tc-ADC in tumour-free mice (Fig. 3a,
Supplementary Tables 3 and 4) as well as its biodistribution in
two TAG72-expressing tumour models: mice-bearing colon
carcinoma xenografts (LS174T) characterised by a relatively high
TAG72 expression, and mice-bearing ovarian carcinoma xeno-
grafts (OVCAR-3) with a lower TAG72 expression (Fig. 3b–d and
Supplementary Fig. 13). The clearance was found to be nearly
complete 2 days post-injection (Fig. 3a), at which point the
tumour uptake in LS174T-tumored mice was 29% injected dose
per gram (ID g−1) (Fig. 3d), matching the high uptake of the
native CC49 mAb in this animal model27,28 and demonstrating
that the diabody conjugate design combines a low systemic
exposure with a high tumour accumulation as compared with
other mAb fragment drug conjugates30. As expected, the uptake
in the OVCAR-3 xenografts was lower at 6% ID g−1, which is still
much higher than the 0.8% ID g−1 uptake in TAG72-negative
HT-29-tumour-bearing mice (Supplementary Table 5). The very
low retention of tc-ADC in blood (<1% ID g−1) and especially in
non-target tissues for both models indicated that an interval of
2 days between ADC and activator administration should lead to
ADC activation with good tumour selectivity. To assess the serum
protein-induced deactivation rate of the TCO linker in vivo, mice
were administered 125I-labelled tc-ADC and blood samples were
obtained over time and reacted ex vivo with an excess of the
highly reactive 177Lu-labelled 3,6-bispyridyl-tetrazine-DOTA
probe 4 (Fig. 2), resulting in IEDDA conjugation of 4 to the
TCO linker of the ADC. Separation of the ADC from unreacted
[177Lu]Lu-4 and quantiﬁcation of the 177Lu/125I ratio led to a
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Fig. 3 Biodistribution of diabody-based anti-TAG72 tc-ADC and the control ADCs vc-ADC (valine-citrulline linker; anti-TAG72) and nb-ADC (non-binding,
anti-PSMA; TCO linker). a Blood kinetics of 125I-labelled tc-ADC administered i.v. at 1 and 5mg kg−1 dose in tumour-free mice (calculated half-lives of 5.95
and 7.17 h, respectively). Immunostaining of b LS174T colon carcinoma and c OVCAR-3 ovarian carcinoma slices showing TAG72 expression (brown
staining). d Biodistribution of 125I-labelled tc-ADC and controls vc-ADC and nb-ADC (2 mg kg−1) 48 h post-injection i.v. in mice-bearing subcutaneous
LS174T and OVCAR-3 xenografts, respectively; blood level of tc-ADC comparable to vc-ADC and to level in tumour-free mice at 48 h (Fig. 3a), while nb-
ADC levels in blood and other tissues are lower due to faster clearance. Data represent the mean percentage injected dose per gram (% ID g−1) with s.d.
(n= 4)
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deactivation half-life of ca. 5.5 days (Supplementary Fig. 15),
matching that of other TCOs23,31 and exceeding the 2 days
needed for the ADC to clear from blood, after which the tumour-
bound fraction can be activated to induce drug release.
Development of the tetrazine activator. The characteristics of
tc-ADC held promise for efﬁcient tumour therapy provided that
a tetrazine activator could be found that enables quantitative
reaction with the tumour-bound ADC and exhibits a high release
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Fig. 4 In vivo assessment of activator 3 and probe 4. a Blood kinetics of 177Lu-labelled 3 administered i.v. at 0.335mmol kg−1 (calculated half-life: 12 min)
and b biodistribution of [177Lu]Lu-3 in tumour-free mice 1 h post-injection. c Blocking study: biodistribution of probe [177Lu]Lu-4 (0.335 µmol kg−1) 3 h
post-injection i.v. in LS174T and OVCAR-3 tumour-bearing mice pretreated i.v. with tc-ADC only (2 mg kg−1) or with tc-ADC followed by 3 (0.335mmol kg
−1); data represent the mean percentage injected dose per gram (% ID g−1) with s.d. (n= 4). d MMAE concentration in LS174T xenografts, plasma and
livers of mice injected with tc-ADC (2 mg kg−1; n= 3) followed 48 h later by activator 3 (0.335mmol kg−1) or vehicle and euthanized 72 or 96 h post-ADC
administration. e Post-mortem SPECT/CT projection of a LS174T tumour-bearing mouse pretreated i.v. with tc-ADC (2mg kg−1) followed 48 h later by the
111In-analogue of 3 (13 nmol kg−1, 13 MBq, i.v.). f SPECT/CT projection of a live LS174T tumour-bearing mouse pretreated i.v. with tc-ADC (2mg kg−1)
followed 48 h later by 111In-labelled 4 (19 nmol kg−1, 24MBq, i.v.). g, h Single transverse slice passing through the tumour of the mouse in resp. e, f White
arrows indicate the tumour; yellow arrows indicate the kidneys; pink arrow indicates the bladder. i Tumour-to-organ ratios of [111In]In-3 with and without
pre-administration of tc-ADC and tumour-to-organ ratios of [111In]In-4 with pre-administration of tc-ADC, derived from the SPECT/CT imaging (n= 2)
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yield. The 3,6-bisalkyl-tetrazine and 3-alkyl-6-aryl-tetrazine
structures that afford cleavage have a lower reactivity compared
to the highly reactive but poorly releasing 3,6-bispyridyl-tetrazine
motif (present in 4), which has successfully been used in IEDDA
conjugations in vivo18,19,28,32. As small molecules, these less
reactive tetrazines likely clear from circulation too fast, precluding
quantitative on-tumour ADC reaction23. For example, small 3,6-
bisalkyl-tetrazines have been shown to clear with half-lives of ca.
1 min33,34. Conjugation to 10 kDa dextran with a clearance half-
life of ca. 6 min35 partially remedied this but at the expense of a
substantially lower maximal release yield of 50%, possibly due to
the dextran microenvironment affecting the formation of the
releasing intermediate23. We, therefore, aimed to replace the
dextran by a smaller moiety that would slow down the blood
clearance without negatively impacting the release yield provided
by the 3,6-bisalkyl-tetrazine motif. Intrigued by the relatively slow
clearance (10 min half-life) of the 3,6-bispyridyl-tetrazine imaging
probe 4, containing a tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA) chelate, used in earlier extracellular pretargeted
imaging studies28, we set out to identify the governing factor. We
prepared an analogue of 4 comprising a PEG11-linked DOTA as
well as an oxime linkage to an 18F-labelled ﬂuorobenzaldehyde
([18F]F-S24, Supplementary Fig. 14a). Pharmacokinetic and
tumour pretargeting studies using pre-administered TCO-tagged
CC49 demonstrated that the blood clearance and tumour uptake
of this probe were similar to those of probe 4 (Supplementary
Fig. 14 and Supplementary Table 2). Surprisingly, [18F]ﬂuor-
obenzaldehyde-labelled derivatives without the chelate, but with a
PEG11, a PEG11-glutamic acid, or only a glutamic acid moiety all
showed a markedly faster blood clearance and a corresponding
lower tumour capture by pre-administered TCO-tagged CC49
(Supplementary Fig. 14). This prompted us to exploit the unex-
pected clearance modulating effect of the DOTA chelate and to
develop PEG11-DOTA conjugated 3-methyl-6-trimethylene-tet-
razine 3 as an ADC activator (Fig. 2). To match the chemical
properties of 177Lu- or 111In-labelled 4 and to avoid an osmolaric
shock in mice treated with higher doses of activator, the DOTA
chelate in 3 was complexed with nonradioactive lutetium(III) (we
chose to use LuCl3 as it has a 26-fold higher LD50 than InCl3).
Next, we assessed the blood clearance and biodistribution of 3
spiked with 177Lu and found a clearance half-life of 12 min
(Fig. 4a), very similar to the value for 4 and exceeding the value
for 10 kD dextran derivatives28,35. Furthermore, [177Lu]Lu-3 had
a complete lack of retention in tissues except some for the kidney,
the organ of excretion (Fig. 4b and Supplementary Table 6).
In vitro release and cytotoxicity. Importantly, the new activator
3 gave 90% drug release upon reaction with tc-ADC in PBS for 1
h at 37 °C, as evidenced by protein mass spectrometry showing
efﬁcient conversion of the ADC to the fully activated product
bearing four pyridazine conjugates derived from 3 without
MMAE (31719.60 Da for the diabody monomer; Figs. 1 and 5a,
and Supplementary Figs. 2a, b and 4). This yield corresponds well
with the 80–85% yield found for the small 3,6-dimethyl-tetrazine
in previous studies19,21,23,32. In serum, the liberation of MMAE
from tc-ADC by 3 occurred at a slightly slower pace, giving 51%
at 1 h and a maximal release of 80% at 20 h (Fig. 5b, c). The actual
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maximal release yield is likely in between 80–90% as the liberated
MMAE is not completely stable in serum solution for long
timeframes and since the 0.1% triﬂuoroacetic acid (TFA) used in
the protein mass spectrometry can favour the pyridazine elim-
ination. The efﬁcacy of this ADC system was reﬂected in cyto-
toxicity assays in LS174T and OVCAR-3 cell cultures. As opposed
to tumours and spheroids, TAG72 expression is very low in cells
grown in monolayers36–39 and, therefore, the ADC activation was
performed in solution in cell culture. The activator alone, shown
to be completely stable in serum at 37 °C for at least 3 h (Sup-
plementary Fig. 10d), was not toxic while tc-ADC alone only
exhibited a relatively moderate toxicity with EC50 values of
respectively 71 nM and 29 nM. However, when a ﬁxed dose of 3
µM activator 3 was combined with the ADC, the cytotoxicity
increased 1000-fold, affording EC50 values of 185 and 35 pM,
matching the toxicity of the parent drug MMAE (Fig. 5d, e and
Supplementary Table 1).
In vivo reaction and release studies. These results led us to
examine the on-tumour reaction between tc-ADC and activator 3
using an in vivo blocking experiment23. In this approach, the
sequential injection of tc-ADC and the nonradioactive activator
(3) 2 days later is followed by administration of the highly
reactive [177Lu]Lu-4 to bind to TCO linker that has not already
reacted with 3, thereby providing a read out on the reaction
between tc-ADC and 3. LS147T-tumour-bearing mice were i.v.
administered 125I-labelled tc-ADC (2 mg kg−1; 0.033 µmol kg−1)
and nonradioactive activator 3 (0.335 mmol kg−1) 48 h later,
followed by [177Lu]Lu-4 (0.335 µmol kg−1) at 50 h. Biodistribu-
tion at 53 h conﬁrmed the high tumour uptake of the ADC
(Supplementary Fig. 16a) and revealed that there was no speciﬁc
tumour uptake of [177Lu]Lu-4 (Fig. 4c), the value being as low as
the uptake of [177Lu]Lu-4 without pre-injection of tc-ADC and
activator23. In contrast, the positive control, tc-ADC followed by
[177Lu]Lu-4 at 50 h, led to an efﬁcient IEDDA reaction and a high
tumour uptake of the probe. Similar results were obtained for the
OVCAR-3 model (Fig. 4c). These data demonstrate that the small
activator 3 leads to a quantitative reaction of the extracellular
tumour-bound tc-ADC. Also, this on-tumour reaction remained
quantitative when the dose of tc-ADC was increased from 2 to 5
and 10 mg kg−1 (Supplementary Fig. 16b, c).
To learn whether the high tumour uptake of tc-ADC and its
complete reaction with 3 resulted in the expected high drug levels
in tumour vs. other tissues, LS174T-bearing mice were adminis-
tered tc-ADC with or without 3 48 h later, followed by
biodistribution at 72 or 96 h post-ADC administration. Liver
and tumour homogenates and plasma were extracted with
methanol followed by MMAE quantiﬁcation with mass spectro-
metry (Fig. 4d). The activation of tumour-bound tc-ADC indeed
gave high and sustained MMAE tumour levels 24 and 48 h after
injection of 3, indicating that tumour washout of MMAE, if any,
is minimal. Furthermore, the MMAE levels were at least a 100-
fold lower in liver and plasma, and in tumours that only received
the ADC and not 3, underlining the very favourable biodistribu-
tion of the ADC, its stability and its tetrazine-dependent release.
The presence of the DOTA chelate in activator 3 presented
the opportunity to directly image the reaction of 3 with the
tumour-bound tc-ADC by 111In-labelling and single photon
emission computed tomography/computed tomography
(SPECT/CT). Despite the ca. 100-fold lower reactivity of 3 (k2
of 54.7 ± 2.2 M−1 s−1 with tc-ADC, Supplementary Fig. 11)
compared to bispyridyl-substituted tetrazines19, the intravenously
administered [111In]In-3 speciﬁcally targeted the tumour-bound
conjugate in mice that were administered tc-ADC 48 h earlier
(tumour-to-muscle ratio of 1.7–2.1, Fig. 4e, g and i), as conﬁrmed
in a biodistribution study (Supplementary Fig. 16d). Moreover,
even at the low imaging dose of 19 nmol kg−1, four orders of
magnitude lower than used in the blocking experiment, [111In]In-
3 efﬁciently distributed throughout the tumour. As expected, a
similar dose of the more reactive probe [111In]In-4 produced a
higher tumour contrast (4.3–6.8 tumour-to-muscle ratio, Fig. 4f,
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h and i) shortly post-injection, suggesting its potential application
as a companion diagnostic, to visualise ADC tumour uptake in
patients before activation and/or to conﬁrm drug release
thereafter.
Therapy studies. On the basis of these favourable results we
embarked on therapy studies in LS174T- and OVCAR-3-tumour-
bearing mice. To evaluate the added beneﬁt of the tetrazine-
cleavable linker for non-internalising ADCs compared to the use
of a protease-cleavable linker, an analogous TAG72-targeted
diabody vc-ADC was prepared with the same valine-citrulline-
linked MMAE as used in Adcetris (2, Fig. 2)1. For a non-binding
control, maleimide-TCO-MMAE 1 was conjugated to an analo-
gous diabody targeting the prostate speciﬁc membrane antigen
(PSMA), affording nb-ADC (Fig. 2). As expected, while vc-ADC
had the same uptake in LS174T and OVCAR-3 xenografts as tc-
ADC, the non-binding control nb-ADC was not retained in the
tumour (Fig. 3d). In addition, both ADCs exhibited the same low
retention in blood and non-target tissues at 48 h post-injection as
tc-ADC. The LS174T-tumoured mice received four cycles within
2 weeks of the combination of tc-ADC with 3 (48 h post-ADC;
0.335 mmol kg−1). The mice that received 1 mg kg−1 tc-ADC
doses did not respond to therapy (Fig. 6a) as their tumours grew
as fast as in the group that only received vehicle (17 days
median survival, Fig. 6c, Supplementary Table 9). However, 3 and
5 mg kg−1 tc-ADC doses gave a pronounced tumour growth
delay of approx. 1 month (P < 0.01 at day 16 with respect to
1 mg kg−1 dose and vehicle, one-way ANOVA with Bonferroni’s
post-test) and an extended median survival of 34 and 39 days. On
the contrary, despite an initial transient effect of vc-ADC, this
ADC and tc-ADC without activator 3, the activator alone, and
nb-ADC in combination with 3 all failed to control tumour
growth when given in four cycles (Fig. 6b), leading to similar
survival outcomes as found for the vehicle (12–14.5 days median
survival; Fig. 6c). These ﬁndings indicate that tc-ADC is stable
in vivo and that its therapeutic effect is dependent on TAG72-
targeted tumour accumulation and the presence of 3. Impor-
tantly, the protease-cleavable linker in the vc-ADC used here as a
control was not effective in the extracellular matrix due to a lower
and possibly slower MMAE release, most likely by extracellular
proteases (Supplementary Fig. 17)16.
A pilot study with OVCAR-3 tumour-bearing mice that received
one single-dose of tc-ADC (0.75, 1.5, 3.75 or 7.5 mg kg−1)
followed by activator 3 (48 h post-ADC; 0.335 mmol kg−1)
already showed a dose-dependent therapeutic response, despite
heterogeneous tumour growth (Supplementary Figs. 19 and 20).
In a multi-dose study, the administration of four cycles
of the combination of tc-ADC (3.75 mg kg−1) with 3
resulted in a pronounced and durable tumour regression with
barely palpable residual tumour masses until the end
of the 4 month study, with 7 out of 8 mice surviving (Fig. 6d–f).
On the contrary, most of the mice that received four cycles
of the vehicle, activator 3 alone or nb-ADC in combination
with 3 developed signiﬁcantly larger tumours (P < 0.05 at day 20)
and had to be removed from the study within 2 months
(41–55 days median survival, Fig. 6d–f, Supplementary
Table 8). Four cycles of tc-ADC alone or vc-ADC produced a
heterogeneous response with a signiﬁcantly larger mean tumour
sizes in the second half of the study (P < 0.01 with tc-ADC alone
at day 41; P < 0.05 with vc-ADC at day 83; Fig. 6e and
Supplementary Fig. 22). While the limited therapeutic effect of
vc-ADC is likely due to extracellular protease-based release16, the
minor effect of tc-ADC alone could suggest that some more
non-speciﬁc MMAE release occurred at time points later than the
earlier surveyed 96 h (for LS174T, Fig. 4d). Despite the partial
therapeutic effect, these groups of mice had a limited median
survival (72–86 days) and only one mouse per group reached the
end of the study (Fig. 6f).
The click-to-release treatment was tolerated well, with
no overt signs of toxicity that could be attributed to the use of
the ADC, the activator or the combination. The LS174T xenograft
is a very aggressive tumour model with a large health burden, as
evidenced by the 5–10% weight-loss excluding tumour weight
experienced in all groups, including the group that only received
vehicle (Supplementary Fig. 23b). No weight losses were recorded
in any of the groups of OVCAR-3 tumour-bearing mice
(Supplementary Fig. 23a). Furthermore, the administration of
four cycles of tc-ADC, activator 3 or tc-ADC followed by
activator 3 had no effect on the levels of haemoglobin, leucocytes
and thrombocytes in blood in tumour-free mice, and no
alterations were observed in the histopathology of kidneys and
liver, conﬁrming lack of toxicity (Fig. 7 and Supplementary
Fig. 24).
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Discussion
ADCs have the potential to improve chemotherapy of solid
tumours, as they allow the use of toxins with orders of magnitude
higher potencies. However, the current approaches are limited to
efﬁciently internalising receptors, which are typically only over-
expressed in a subset of solid tumour patient populations. There
are non-internalising receptors and stroma proteins that would be
attractive targets if there were a way to selectively release the drug
extracellularly. We hypothesised that the use of exogenous
chemistry instead of relying on endogenous drug release
mechanisms may enable the development of a novel class of
ADCs that does not require internalisation, complementing
current approaches and thereby expanding the application scope
of this powerful therapeutic modality. Herein we report the ﬁrst
example of therapy using bioorthogonally triggered drug release
from a targeting agent in vivo. To this end, we developed a fast
clearing ADC based on a diabody, designed to release MMAE
through the IEDDA pyridazine elimination. While ADCs based
on mAb fragments are usually hampered by low or modest target
uptake due to fast clearance after i.v. injection, reducing the renal
clearance rate by PEGylation led to a favourable combination of
characteristics of mAbs and peptides. The diabody ADC matched
the high tumour localisation of its parent mAb but cleared much
faster from blood allowing the i.v. administration of the tetrazine
activator 2 days later, leading to efﬁcient extracellular activation
and high MMAE tumour levels with no or minimal washout. This
temporally controlled and traceless cleavage was independent
from endogenous release mechanisms and tumour selective due
to the very low retention of the diabody conjugate in non-target
tissues, minimising toxicity. This is exempliﬁed by the 2 orders
of magnitude lower levels of MMAE in plasma and liver for
tc-ADC+ 3, and in tumour for tc-ADC alone. The lack of an Fc
region and the resulting low systemic exposure may in the future
also prove beneﬁcial in limiting the off-target payload deposition
that is currently hampering the ADCs in clinical trials2. In the
course of developing the approach we found that the DOTA
chelate can be used to reduce the clearance rate of certain tetra-
zine structures, thereby boosting in vivo reaction yields of tetra-
zine moieties that give high release yields. Furthermore, the use of
a DOTA chelate enabled direct imaging of the reaction of the
tetrazine with the tumour-bound ADC, demonstrating good
intra-tumour distribution of the activator and potentially allow-
ing future theranostic approaches. While the tetrazine dose was
relatively high, the human equivalent dose (36 mg kg−1) is, for
example, still one to two orders of magnitude lower than the
doses typically used for iodinated CT contrast agents in the clinic.
The combination of ADC and activator led to a strong anticancer
activity in vitro (EC50 185 and 35 pM), and in vivo in mice
bearing, respectively, colorectal (LS174T) and ovarian (OVCAR-
3) cancer xenografts. In addition to controlling tumour growth in
the aggressive LS174T model, the click-cleavable conjugate
resulted in a strong and durable response in OVCAR-3 mice at
practical dose levels, leading to survival without any signs of
toxicity for 4 months. On the contrary, the gold standard control,
the same diabody conjugated with the protease-cleavable linker-
payload combination used in the FDA approved Adcetris, was
not effective in these tumour models, underlining the need for
alternative activation mechanisms to complement the existing
ADC therapies. Although a two-step approach requires the
clinical development of two components and the optimisation of
their dosing, this may partially be off-set by developing an ADC
against a pan-carcinoma target and by the fact that the same
activator can be used for different targets. In this respect, the
CC49 diabody conjugate is very interesting as TAG72 is expressed
in a wide range of solid cancers, but the click-to-release concept
can also be extended to other targets and targeting agents.
Furthermore, extracellular cleavage may hold promise for a more
homogeneous drug distribution in tumours, possibly even
reaching cancer stem cells8. Another tempting avenue to explore
is whether extracellular release can augment the recently observed
activation of tumour-resident dendritic cells by tubulin inhibitors
leading to antitumour immune responses40. In summary, with
one FDA approved solid tumour ADC and approx. 5 more in
pivotal trials there is a need to increase the number of viable
targets. This study clearly suggests that a click-to-release system
can expand the scope of the successful ADC concept to non-
internalising receptors and stroma targets that have so far
remained out of reach of ADC therapy.
Methods
Additional methods and corresponding ﬁgures are provided in the Supplementary
Methods and Supplementary Figures, including synthesis and characterisation of
all new compounds (Supplementary Figs. 25–76) and diabody conjugates (Sup-
plementary Figs. 1–3 and 8), radiolabelling (Supplementary Figs. 8 and 10a–c) and
several in vivo experiments (Supplementary Figs. 14–24).
Stability and activation of diabody conjugates in PBS. The stability of stock
solutions of diabody conjugates at 4 °C was monitored by quadrupole time-of-ﬂight
mass spectrometry (QTOF-MS). An aliquot of the stock solution (10 μL 2 μg μL−1
in phosphate buffer pH 6.8 containing 2 mM ethylenediamine-tetraacetic acid
(EDTA-PB) and 5% dimethylsulfoxide (DMSO)) was diluted with PBS (90 μL), and
analysed with high-performance liquid chromatography (HPLC)-QTOF-MS. This
procedure was repeated over the course of several months (6 months for tc-ADC
and nb-ADC, and 18 months for vc-ADC). No degradation of the diabody con-
jugates was observed in this time frame (Supplementary Figs. 2 and 3). Aliquots of
stock solutions of tc-ADC and nb-ADC (10 μL 2 μg μL−1 in 5% DMSO/EDTA-PB)
were diluted with PBS (90 μL), mixed with activator 3 (5 μL 2.5 mM in PBS; 1.25 ×
10−8 mol) and incubated at 37 °C for 1 h. Subsequent HPLC-QTOF-MS analysis
demonstrated the formation of free MMAE (m/z=+ 718.51 Da) and the diabody
reaction products without MMAE (Supplementary Figs. 4 and 5).
Stability of activator 3 in mouse serum. Lutetium-177-labelled activator 3 (11
nmol, ca. 20MBq) was incubated in 50% mouse serum in PBS (0.7 mL) at 37 °C (n
= 3). At t= 0, 30 min, 1, 2 and 3 h, 100 µL aliquots of the mixture were taken,
treated with 100 µL ice-cold acetonitrile, mixed and centrifuged for 5 min at 13,000
rpm. More than 90% of the radioactivity was recovered in the supernatant at all
time points. The supernatant was ﬁltered through a 0.22 µm ﬁlter, 2.5-fold diluted
with PBS and analysed by radio-HPLC. Linear regression of the % intact activator
(peak at 10.3 min in Supplementary Fig. 10b) over time afforded an extrapolated
half-life of ca. 54 h (Supplementary Fig. 10d).
Activation of diabody conjugates in mouse serum. tc-ADC stock solution (2 μg
μL−1 in 5% DMSO/EDTA-PB) was tenfold diluted with PBS. Subsequently 50 μL
of this solution was twofold diluted with mouse serum and activator 3 was added
(6.5 μL, 5 mM in PBS) followed by incubation at 37 °C. After 10 min, 1 h and 20 h
aliquots of the solution were taken and proteins were precipitated by adding two
parts of ice-cold acetonitrile. After vortexing, 10 min standing at −20 °C and
centrifugation (13,000 rpm, 5 min), the supernatants were separated from the
protein pellets, diluted with ﬁve parts of PBS and analysed by HPLC-QTOF-MS
(Supplementary Fig. 7). MMAE recovery was quantiﬁed using calibration curves in
50% mouse serum, which were processed in the same manner. Reactions were
performed in triplicate.
Cell culture and proliferation assays. The cell lines used in this study were
obtained from the American Type Culture Collection. The human colon cancer
LS174T and HT-29 cell lines were cultured in RPMI-1640 medium supplemented
with 2 mM glutamine and 10% heat inactivated fetal calf serum (FCS). The human
ovary carcinoma NIH:OVCAR-3 cell line was cultured in RPMI-1640 medium
supplemented with 1 mM sodium pyruvate, 10 mM HEPES, 2 mM glutamine, 10
µg mL−1 bovine insulin and 20% FCS. Twenty-four hours prior to the experiment,
the cells were plated in 96-well plates at a 5000 cells/well density. Activator 3 (52
mM in PBS containing 5% DMSO), tc-ADC (2.36 µg µL−1 in EDTA-PB containing
5% DMSO) and MMAE (63 µM in DMSO) were serially diluted in pre-warmed
culture medium immediately before the experiment and added to the wells (200 µL
ﬁnal volume per well; n= 3). The tc-ADC was either added alone or followed by 3
µM activator (5 eq. with respect to the highest TCO concentration). After 72 h
incubation at 37 °C, cell proliferation was assessed by an MTT assay. The pro-
liferation assay was performed in triplicate. EC50 values (Supplementary Table 1)
were derived from normalised cell growth curves generated with GraphPad Prism.
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Animal studies. The animal studies were performed in accordance with the
principles established by the revised Dutch Act on Animal Experimentation (1997)
and were approved by the institutional Animal Welfare Committee of the Radboud
University Nijmegen. To determine the appropriate group sizes for the different
experiments, the sample size calculation tool from the University of Iowa was used
(http://homepage.stat.uiowa.edu/~rlenth/Power/index.html). Female BALB/c nude
mice (7–9-week-old, 18–22 g body weight; Charles River Laboratories and Janvier)
were subcutaneously inoculated ca. 3 × 106 LS174T cells (in 100 µL complete cul-
ture medium), ca. 5 × 106 NIH:OVCAR-3 cells (in 100 µL 1:1 RPMI-1640: matri-
gel) or 5 × 106 HT-29 cells (in 100 µL complete culture medium) in the hind limb.
Tumour size was determined by caliper measurements in three dimensions
(tumour volume=½× l ×w × h) once per week (OVCAR-3) or three times per
week (LS174T) by a blinded biotechnician. Biodistribution and imaging studies
started when the tumours reached 0.1–0.2 cm3. Animals were randomly allocated
to treatments groups. At the end of the studies, the animals were euthanized, blood
was obtained by cardiac puncture and organs and tissues of interest were harvested,
blotted dry, weighed, added with 1 mL PBS and the sample radioactivity was
measured in a shielded well-type γ-counter together with aliquots of the injected
dose to calculate % ID g−1 and % ID. Stomachs and intestines were not emptied
before γ-counting.
ADC blood kinetics and biodistribution. Two groups of tumour-free mice (n= 4)
were injected with 125I-labelled tc-ADC at 1 and 5 mg kg−1 dose (ca. 0.4 MBq in
100 µL saline per mouse). The mice were serially bled via the vena saphena (ca. 20
µL samples) at various times between 5 min and 72 h post-injection. Four days
post-injection the mice were euthanized, one last blood sample was obtained via
cardiac puncture and selected organs and tissues were harvested for γ-counting
(Supplementary Table 4). The blood values were ﬁt to a two-exponential curve and
the pharmacokinetics parameters were calculated (Supplementary Table 3).
ADC tumour targeting. Groups of mice bearing subcutaneous LS174T, OVCAR-3
or HT-29 xenografts (n= 3–4) were injected with 125I-labelled tc-ADC, vc-ADC
or nb-ADC at 2 mg kg−1 dose (0.35–0.40 MBq in 100 µL saline per mouse). All
mice were euthanized 48 h post-ADC injection and blood, tumours and other
organs were harvested for γ-counting.
Activator blood kinetics and biodistribution. The activator precursor S4
(see Supplementary Methods) was radiolabelled with 177Lu at ca. 1 MBq nmol−1
molar activity and the resulting product was used to spike the nonradioactive
activator 3. Two groups of four tumour-free mice were injected with [177Lu]Lu-3
(0.335 mmol kg−1, ca. 1.5 MBq in 130 µL PBS containing 5% DMSO per mouse).
One group was euthanized 1 h post-injection. The second group was serially bled at
various times between 2 and 90 min post-injection and euthanized 24 h post-
injection. Selected organs and tissues were harvested from all mice for γ-counting
(Supplementary Table 6).
In vivo reaction between ADC and activator: tumour blocking studies. Two
groups of mice (n= 4) bearing LS174T or OVCAR-3 xenografts were injected with
125I-labelled tc-ADC (2 mg kg−1, ca. 0.35MBq in 100 µL saline per mouse) fol-
lowed 48 h later by activator 3 (0.335 mmol kg−1, in 130 µL PBS containing 5%
DMSO) and, after 1 h, by [177Lu]Lu-4 (0.335 µmol kg−1, ca. 1.5 MBq in 100 µL
saline per mouse). Two more groups of mice (n= 4 for LS174T and n= 3 for
OVCAR-3) were injected with the same amount of 125I-labelled ADC followed
only by probe 4 49 h later. All mice were euthanized 3 h post-probe injection and
the 125I/177Lu uptake in tumours and other organs and tissues was measured by γ-
counting with a dual-isotope protocol with cross contamination correction. To
evaluate the effect of ADC dose on the reaction efﬁcacy with 3 (0.335 mmol kg−1),
three more groups of mice bearing LS174T xenografts were injected with 125I-
labelled tc-ADC at 1, 5 and 10 mg kg−1 dose (0.35–0.40 MBq in 100 µL saline per
mouse) and evaluated as outlined above.
In vivo reaction between ADC and activator or probe: SPECT/CT imaging.
Two LS174T tumour-bearing mice pretreated with tc-ADC (2 mg kg−1, 48 h before
activator injection) and two non-pretreated mice were injected with 111In-labelled
activator 3 (13–19 nmol kg−1, 13–20MBq in 100 µL saline containing 100 µg
gentisic acid per mouse), derived from precursor S4. Two more tc-ADC pretreated
mice were injected with 111In-labelled probe 4 (ca. 19 nmol kg−1, ca. 24 MBq in
100 µL saline containing 100 µg gentisic acid per mouse). The mice that received
[111In]In-3 were euthanized 3 h post-activator injection, bladders were voided of
residual radioactive urine and the mice were imaged post-mortem. The mice that
received [111In]In-4 were anaesthetised 2 h post-injection and were imaged under
anaesthesia (ca. 45 min imaging). Representative SPECT/CT images of a non-
pretreated mouse injected with [111In]In-3 are depicted in Supplementary Fig. 18.
Therapy studies. Therapy studies where performed when tumours were clearly
palpable (55 ± 26 mm3 LS174T tumour size, 5–7 days post-cell inoculation; 115 ±
43 mm3 OVCAR-3 tumour size, 6–8 weeks post-cell inoculation). A pilot (single-
dose) therapy study in mice bearing OVCAR-3 xenografts is reported in the
Supplementary Information (Supplementary Figs. 19 and 20, Supplementary
Table 7). Multi-dose therapy studies were performed following the injection
scheme in Supplementary Fig. 21. Two groups of OVCAR-3 tumour-bearing mice
(n= 8) received four cycles of TCO-containing ADC (tc-ADC or nb-ADC)
at a 3.75 mg kg−1 dose (in 100 µL PBS containing 5% DMSO) and activator 3
(0.335 mmol kg−1 in 130 µL PBS containing 5% DMSO). Two groups of mice
(n= 8) were injected with four cycles of vc-ADC or tc-ADC at the same dose
followed by vehicle and, ﬁnally, two more groups of mice (n= 8) received four
cycles of either the activator or vehicle. Four groups of LS174T tumour-bearing
mice (n= 8–10) were injected with four cycles of increasing doses of tc-ADC (1, 3
and 5 mg kg−1 in 100 µL PBS containing 5% DMSO) or nb-ADC (3 mg kg−1) and
activator 3 (0.335 mmol kg−1 in 130 µL PBS containing 5% DMSO). Two groups of
mice (n= 10) were administered four cycles of 3 mg kg−1 vc-ADC or tc-ADC
followed by vehicle and two more groups of mice (n= 10) received four cycles of
either the activator or vehicle only. In both experiments, the animals were ran-
domly grouped, monitored daily by experienced biotechnicians, and were removed
from the study in case of poor physical condition (e.g., discomfort, reduced
motility), in case of excessive body weight loss (>20% with respect to baseline or
>15% in two consecutive measurements) or when tumours reached a 1 cm3 size. If
none of these conditions occurred the mice were maintained in the study for up to
2 months (LS174T tumour model) or 4 months (OVCAR-3 tumour model). At
mouse euthanasia, selected organs (kidney, liver and spleen) were harvested and
formaldehyde-ﬁxed for histopathology.
Histology and haematological toxicity. Four separate groups of tumour-free mice
(n= 3) received four cycles of tc-ADC (5 mg kg−1) and activator 3 (0.335 nmol kg
−1), tc-ADC only, activator only or vehicle, according to the injection scheme in
Supplementary Fig. 21. Blood samples were collected from these mice before
treatment (day 0), after treatment (day 15) and at euthanasia (day 34) to assess
haematological toxicity (haemoglobin, leucocytes and thrombocytes levels). Kidney
sections from these mice and from random mice in the multi-dose therapy groups
were stained with hematoxylin-eosin and periodic acid Schiff reagent (PAS). Liver
slices were stained with hematoxylin-eosin. Renal damage was microscopically
graded from 0 (no damage) to 4 (severe damage) by an experienced pathologist,
according to Supplementary Table 1012.
Data analysis. Curve ﬁtting, linear regressions and area-under-the-curve calcu-
lations were performed with GraphPad Prism (v 5.01). Group comparisons were
performed with one-way ANOVA (with Bonferroni’s post-tests) or two-tailed t-
tests. Survival curves were compared with the log-rank (Mantel-Cox) test. Differ-
ences between data sets were considered signiﬁcant when P < 0.05.
Data availability. The data that support the ﬁndings reported herein are available
on reasonable request from the corresponding author.
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